Interferon-adjacent peptide mimetics

This is a research category rather than a defined molecule, so sequence length and molecular weight are genuinely not specifiable. The best-developed approach uses short peptides corresponding to the C-terminal region of IFN-gamma or the interferon receptor's cytoplasmic domain, delivered into cells with a lipophilic or cell-penetrating tag; once inside they engage the JAK-STAT machinery directly, bypassing the extracellular receptor. The rationale is that full cytokine binding at the cell surface triggers the whole downstream program including the fever, flu-like syndrome, cytopenias and depression that make interferon therapy so unpleasant, whereas intracellular mimetics may activate a narrower antiviral or antiproliferative subset. Antiviral and antitumour activity has been shown in cell and rodent models. No candidate from this class has completed a meaningful human trial.

Targets: JAK1 / TYK2, STAT1 / STAT2, Interferon receptor cytoplasmic domain

• · No dosing exists for this class in humans. Any vendor supplying a product under this name with a suggested dose is inventing the number - there is no trial, no label and no pharmacokinetic study to derive it from.

Work out your exact syringe units →

• commonUnknown - no human safety data— This is the honest answer. No human exposure dataset exists for this class.
• rareTheoretical interferon-like syndrome— If a mimetic worked well enough, fever, myalgia and cytopenias would be the expected class effects.

• Autoimmune disease - interferon signalling is a driver in lupus and several other conditions, so anything that mimics it is the wrong direction.
• Any use outside a laboratory setting, given the complete absence of human data.

• conflictImmunosuppressants — Opposing pharmacology.
• cautionthymosin-alpha-1 — Both push toward Th1/interferon-driven immunity; additive effects would be unpredictable.

• · Not applicable - no human use is established.

No approved product; entirely preclinical research material.

• Johnson and colleagues, intracellular interferon mimetic peptide preclinical research programme (preclinical)
• Reviews of peptide mimetics of cytokine signalling (review)

The design premise is worth understanding because it is genuinely clever and it explains why nothing has reached the clinic. Full interferon binding at the extracellular receptor surface triggers the complete downstream programme - the antiviral and antiproliferative effects you want, plus the fever, flu-like syndrome, cytopenias and depression that make interferon therapy so poorly tolerated. The mimetic hypothesis is that a peptide corresponding to the interferon C-terminus or the receptor's cytoplasmic domain, delivered inside the cell, could engage the JAK-STAT machinery directly and activate a narrower subset of that programme. Mujtaba's 2006 work is the strongest demonstration: IFN-gamma(95-133) prevented encephalomyocarditis virus infection both in tissue culture and in mice, which is a real antiviral effect from an intracellularly delivered peptide. A parallel and conceptually inverted line from the same laboratory targets SOCS1, the suppressor of cytokine signalling that normally shuts interferon responses down - Flowers' JAK2-mimicking peptide and Ahmed's small molecule SOCS antagonist both enhance antiviral immunity by removing a brake rather than pressing an accelerator. Both approaches are legitimate published academic work. Neither has produced a candidate with human data. The gap between an antiviral effect in a mouse and a drug is the entirety of development, and for this class it has not been crossed.

The concrete failure is commercial rather than pharmacological, because there is no pharmacology to fail. No dosing exists for this class in humans. Any vendor supplying a product under this name with a suggested dose has invented the number - there is no trial, no label and no pharmacokinetic study to derive one from, and there is no way for a buyer to verify that the vial contains the peptide claimed, since the class has no single defined molecule. If a mimetic did work as designed, the expected class effects would be exactly the interferon syndrome the approach was meant to avoid: fever, myalgia, cytopenias and mood disturbance. And in anyone with lupus or another interferon-driven autoimmune condition, a working interferon mimetic would be actively harmful, which is why the contraindication is not hypothetical caution.

• JAK1 and TYK2 — No binding constants published for any candidate in this class

  Intracellular engagement of the interferon signalling kinases, bypassing the extracellular receptor. Demonstrated in cell culture.

• STAT1 and STAT2 — Not quantified

  Activation of interferon-stimulated gene transcription, which is the readout used in the preclinical work.

• SOCS1 (suppressor of cytokine signalling 1) — Not quantified

  The inverted approach - antagonising SOCS1 removes the negative feedback brake on interferon signalling, enhancing antiviral immunity. Demonstrated with a JAK2 kinase inhibitory region mimetic peptide and with a small molecule antagonist.

• Interferon receptor cytoplasmic domain — Not quantified

  The docking site the mimetic designs are built around.

Not established in humans at any timescale, because no human has been dosed in a published study. In the rodent antiviral models the protective effect was measured over the course of an acute viral challenge, on the order of days. Nothing beyond that can be honestly stated.

There is nothing to stack. No candidate has a dose, a route or a human exposure, and combining an unvalidated research material with anything else compounds unknowns rather than adding effects. The theoretical concern worth recording is that anything mimicking interferon signalling would be expected to be additive with other Th1 and interferon-driving compounds in this class, particularly thymosin alpha-1, and interferon signalling is a genuine disease driver in lupus and several other autoimmune conditions. That is the direction of harm to think about if such a compound ever becomes real.

This entry exists for completeness rather than because the compounds are usable, and the honest comparison is against the drug they are trying to replace. Recombinant interferon alfa is an approved drug with decades of use in hepatitis and oncology, and its problem has never been efficacy - it is tolerability. The mimetic concept is an attempt to keep the antiviral and antiproliferative effects while dropping the systemic toxicity, and after roughly two decades of academic work it has produced good cell-culture and rodent data and no clinical candidate. Within this class, note the contrast with thymosin alpha-1, which pushes interferon-flavoured immunity through TLR9 and has phase 3 data, and which is what someone actually reaching for interferon-like immune effects should be looking at. Against every other entry in this dataset, the interferon mimetics have the least developed evidence for human use of anything here except Crystagen - and unlike Crystagen, at least the underlying academic work is specific, indexed and mechanistically serious.

Deliberately null. No standardised product exists, so there is no meaningful cost. Anything sold under this name is unverified research material of unknown identity.

• ?This is a research category rather than a defined molecule, so sequence, molecular weight and all pharmacokinetic parameters are genuinely unspecifiable rather than merely unreported.
• ?No candidate has completed a meaningful human trial. The trials array is empty for that reason.
• ?No binding affinity has been published for any candidate against JAK1, TYK2, STAT1, STAT2 or SOCS1.
• ?The intracellular delivery problem - getting a peptide across a plasma membrane in therapeutically useful quantity - has not been solved for this class and is the limiting issue rather than a technical detail.
• ?Whether an intracellularly delivered mimetic actually activates a narrower subset of interferon-stimulated genes than full receptor engagement, which is the entire premise, has not been demonstrated in a human system.
• ?Products sold under this name have no verified identity, no verified activity and no basis for any suggested dose.
• ?The relationship between the interferon-agonist strand and the SOCS-antagonist strand of this research programme is conceptual rather than pharmacological - they are opposite interventions grouped together by shared authorship and shared goal, which is worth knowing when reading vendor material that conflates them.

• The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma(95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice Mujtaba MG, Patel CB, Patel RA, et al., Clinical and Vaccine Immunology, 2006 · PMID 16893996

  The clearest demonstration that an intracellularly delivered interferon mimetic peptide produces a real antiviral effect in a whole animal. This is the high-water mark for the class.

• Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function Flowers LO, Subramaniam PS, Johnson HM, Journal of Immunology, 2004 · PMID 15187130

  The SOCS1-mimetic line of work, which is the conceptual inverse of an interferon agonist and part of the same research programme.

• Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling Ahmed CM, Dabelic R, Waiboci LW, et al., Journal of Immunology, 2010 · PMID 20543109

  Removing the SOCS brake to enhance antiviral immunity - the most developed strand of this programme.